SCHEDULE 13G/A: Tang Capital Entities Reaffirm 6.3% Stake in ALX Oncology Holdings
Beneficial Ownership Disclosure
Tang Capital Management, Kevin Tang, and Tang Capital Partners have jointly filed an amended Schedule 13G, reaffirming their beneficial ownership of 6.3% of ALX Oncology Holdings, Inc.'s common stock as of December 31, 2024.
Summary
- Tang Capital Management, LLC, Kevin Tang, and Tang Capital Partners, LP, along with their affiliates Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc., have filed an amended Schedule 13G.
- The filing reports their beneficial ownership in ALX Oncology Holdings, Inc. (ALXO).
- As of December 31, 2024, the reporting persons collectively beneficially own 3,296,883 shares of ALX Oncology Holdings, Inc. Common Stock.
- This represents 6.3% of the total outstanding Common Stock of ALX Oncology Holdings, Inc.
- The percentage is based on 52,743,104 shares outstanding as of October 31, 2024, as reported in the Issuer's Form 10-Q filed on November 7, 2024.
- Tang Capital Management, LLC, Kevin Tang, and Tang Capital Partners, LP share both voting and dispositive power over all 3,296,883 shares.
- Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc. reported 0 shares beneficially owned.
- The shares were not acquired for the purpose of changing or influencing the control of ALX Oncology Holdings, Inc., nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of beneficial ownership. The reaffirmation of a significant stake by an institutional investor can be viewed as a moderately positive signal of continued confidence, but it does not contain new operational or financial news.
Positives
- Reaffirmation of a significant 6.3% stake by institutional investors (Tang Capital entities) in ALX Oncology Holdings, Inc., indicating continued confidence in the company.
Risks
- The filing explicitly states that the shares were not acquired for the purpose of changing or influencing the control of the issuer, which mitigates the risk of an immediate hostile takeover attempt by these specific filers.
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from ALX Oncology Holdings, Inc. or the reporting persons regarding the issuer's future performance.
Industry Context
This Schedule 13G filing is a standard regulatory disclosure of significant beneficial ownership by an institutional investor in a publicly traded company. It does not provide specific industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The continued significant stake by Tang Capital entities may instill confidence among other investors, signaling a belief in the company's long-term prospects.
Key Dates
| Date | Description |
|---|---|
| 2024-10-31 | Date of 52,743,104 shares of Common Stock outstanding as reported in Issuer's Form 10-Q. |
| 2024-11-07 | Date Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership reporting date). |
| 2025-02-14 | Date of filing and signature for the Schedule 13G Amendment No. 1. |
Keywords
ALX Oncology Holdings, ALXO, Tang Capital Management, Kevin Tang, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Healthcare Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.